With the recent CLIA lab certification (the US lab in San Diego), Biovica is moving into the next st...
2023e order book forecast increased by 4% 2023e-24e revenue, EBIT (before s.
Ascelia is preparing and planning for the launch, and the activities are now expected to shift gear ...
I samband med att aXichem AB (publ) (”aXichem” eller ”Bolaget”) genomför sin företrädesemission har ...
Oro för en annalkande lågkonjunktur till följd av b.
Starkt tredje kvartal Systemair redovisar fortsatt stark tillväxt i Q3’22/23.
Redeye initiates coverage of Scandinavian ChemoTech, a Swedish medtech company in early-stage commer...
Redeye comments on W5’s announcement that it has signed a letter of intent to acquire Kongsberg Targ...
Redeye is optimistic about Lipigon’s leading candidate Lipisense after demonstrating a good safety p...
Redeye endorses the positive results announced by InDex Pharmaceuticals regarding the PK study in pa...
Redeye adjusts its estimates ahead of Friday's Q4 report.
Cantargia is a clinical-stage biotechnology company with lead asset nadunolimab (CAN04) under assess...
Redeye is positively surprised by Arise’s strategic partnership and acquisition of 51% of the Finnis...
Långsammare rekrytering för ABNCoV2 fas 3-studie, utspädningseffekter samt lägre prognoser sänker mo...
Redeye comments on Zordix/Maximum Entertainments completion of the acquisition of Fun Labs which wil...
Redeye comments on Heliospectra’s rights issue, announced earlier this morning.
Det avslutande kvartalet för år 2022 är presenterat och vi kan därmed summera det gångna året som et...
Jumpgate avslutar 2022 med god kostnadskontroll, stark tillväxt och en rekordstor order samt ett gen...
Mangold uppdaterar medicinteknikbolaget Lumito, som utvecklat en ny digital avbildningsteknik för bä...
The outcome of Amniotic’s rights issue was announced yesterday, March 13.
